Brendan C. Bender

1.4k total citations
32 papers, 1.1k citations indexed

About

Brendan C. Bender is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Organic Chemistry. According to data from OpenAlex, Brendan C. Bender has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 11 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Organic Chemistry. Recurrent topics in Brendan C. Bender's work include Monoclonal and Polyclonal Antibodies Research (11 papers), Pneumocystis jirovecii pneumonia detection and treatment (9 papers) and Synthesis and Biological Evaluation (9 papers). Brendan C. Bender is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), Pneumocystis jirovecii pneumonia detection and treatment (9 papers) and Synthesis and Biological Evaluation (9 papers). Brendan C. Bender collaborates with scholars based in United States, Canada and Sweden. Brendan C. Bender's co-authors include James Edwin Hall, Richard R. Tidwell, Donald R. McCurdy, Lena E. Friberg, W. David Wilson, David W. Boykin, Arvind Kumar, David W. Boykin, Arvind Kumar and Farial A. Tanious and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Brendan C. Bender

29 papers receiving 1.1k citations

Peers

Countries citing papers authored by Brendan C. Bender

Since Specialization

Citations

This map shows the geographic impact of Brendan C. Bender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendan C. Bender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendan C. Bender more than expected).

Fields of papers citing papers by Brendan C. Bender

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brendan C. Bender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendan C. Bender. The network helps show where Brendan C. Bender may publish in the future.

Co-authorship network of co-authors of Brendan C. Bender

This figure shows the co-authorship network connecting the top 25 collaborators of Brendan C. Bender. A scholar is included among the top collaborators of Brendan C. Bender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brendan C. Bender. Brendan C. Bender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies 2024 ·Clinical Cancer Research ·(unknown), Brendan C. Bender, Zao Li, David C. Turner, (unknown), Anton Belousov, Chi‐Chung Li	11
2	A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma 2024 ·Clinical Pharmacology & Therapeutics ·Chi‐Chung Li, Brendan C. Bender, Justin Wilkins, (unknown), David C. Turner, Bei Wang, Rong Deng, Shweta Vadhavkar, Zao Li, Antonia Kwan, Huang Huang, Kun Peng, Elicia Penuel, Ling‐Yuh Huw, Pascal Chanu, (unknown), (unknown), (unknown), (unknown)	3
3	Cytokine Release Syndrome: Trends with T Cell Engaging Bispecifics from a Systematic Review of Licensing Applications 2024 ·Blood ·(unknown), Brendan C. Bender, Zao Li, David C. Turner, (unknown), Anton Belousov, Chi‐Chung Li	1
4	Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies 2024 ·The Journal of Prevention of Alzheimer s Disease ·Ramakrishnan Veerabathiran, Brendan C. Bender, Jurgen Langenhorst, Maria Magnusson, Michael Dolton, (unknown), Reina N. Fuji, Cecília Monteiro, Edmond Teng, Nastya Kassir, (unknown)	3
5	Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma 2024 ·Clinical and Translational Science ·Brendan C. Bender, Chi‐Chung Li, Mathilde Marchand, David C. Turner, (unknown), Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Y. Jin, Chunze Li, (unknown), (unknown), Pascal Chanu	7
6	Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel 2021 ·CPT Pharmacometrics & Systems Pharmacology ·Sreenath M. Krishnan, (unknown), Brendan C. Bender, Angelica Quartino, Lena E. Friberg	12
7	Deep learning prediction of patient response time course from early data via neural-pharmacokinetic/pharmacodynamic modelling 2021 ·Nature Machine Intelligence ·James Lu, Brendan C. Bender, Jin Y. Jin, Yuanfang Guan	48
8	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts 2020 ·Blood ·Matthew J. Matasar, Chan Y. Cheah, Dok Hyun Yoon, Sarit Assouline, Nancy L. Bartlett, Matthew Ku, Pratyush Giri, Anna Johnston, Ian W. Flinn, André Goy, Dimitrios Tzachanis, Carol O’Hear, Shen Yin, Iris To, (unknown), Chi‐Chung Li, Brendan C. Bender, Elicia Penuel, Huang Huang, Lihua E. Budde	27
9	Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2- Breast Cancer 2016 ·KTH Publication Database DiVA (KTH Royal Institute of Technology) ·Brendan C. Bender	3
10	A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer 2014 ·The AAPS Journal ·Brendan C. Bender, Douglas D. Leipold, Keyang Xu, Ben‐Quan Shen, Jay Tibbitts, Lena E. Friberg	64
11	Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development 2013 ·Clinical Cancer Research ·Hong Xiang, Brendan C. Bender, Arthur E. Reyes, Mark Merchant, Nelson L. ‘Shasha’ Jumbe, Mally Romero, (unknown), Ihsan Nijem, Elaine Mai, Judy Young, Amy Peterson, Lisa A. Damico‐Beyer	28
12	A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer 2012 ·Cancer Chemotherapy and Pharmacology ·Brendan C. Bender, (unknown), (unknown), Amita Joshi, Yu‐Waye Chu, Hope S. Rugo, Ian E. Krop, Sandhya Girish, Lena E. Friberg, Manish Gupta	66
13	Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia 2012 ·Cancer Chemotherapy and Pharmacology ·(unknown), Brendan C. Bender, Morten Krogh Jensen, Ove Juul Nielsen, Lena E. Friberg, Per Hartvig Honoré	28
14	539 POSTER Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMAb 2008 ·European Journal of Cancer Supplements ·Brendan C. Bender, Hong Xiang, Arthur E. Reyes, Lisa A. Damico, (unknown), Amy Peterson, William F. Forrest, Nelson L. ‘Shasha’ Jumbe	1
15	Pharmacokinetic study of ranibizumab (LucentisTM) following subconjunctival, intracameral and intravitreal administration in rabbits 2004 ·Investigative Ophthalmology & Visual Science ·Lisa A. Damico, Jacques Gaudreault, Brendan C. Bender, Jeriza Rusit, (unknown), (unknown), Peter C. Haughney	1
16	Synthesis and anti-Pneumocystis carinii pneumonia activity of novel dicationic dibenzothiophenes and orally active prodrugs 1999 ·European Journal of Medicinal Chemistry ·Donald A. Patrick, James Edwin Hall, Brendan C. Bender, Donald R. McCurdy, W. David Wilson, Farial A. Tanious, (unknown), Richard R. Tidwell	27
17	Prodrugs for Amidines: Synthesis and Anti-Pneumocystis carinii Activity of Carbamates of 2,5-Bis(4-amidinophenyl)furan 1999 ·Journal of Medicinal Chemistry ·(unknown), James Edwin Hall, Brendan C. Bender, Donald R. McCurdy, Richard R. Tidwell, David W. Boykin	82
18	2,5-Bis[4-(N-alkylamidino)phenyl]furans as Anti-Pneumocystis carinii Agents 1998 ·Journal of Medicinal Chemistry ·David W. Boykin, Arvind Kumar, Ge� Xiao, W. David Wilson, Brendan C. Bender, Donald R. McCurdy, James Edwin Hall, Richard R. Tidwell	98
19	Extended Aromatic Furan Amidino Derivatives as Anti-Pneumocystis carinii Agents 1998 ·Journal of Medicinal Chemistry ·(unknown), W. David Wilson, Brendan C. Bender, Donald R. McCurdy, James Edwin Hall, Richard R. Tidwell, Arvind Kumar, (unknown), David W. Boykin	180
20	Anti-Pneumocystis carinii pneumonia activity of dicationic carbazoles 1997 ·European Journal of Medicinal Chemistry ·Donald A. Patrick, (unknown), (unknown), Farial A. Tanious, Jarosław Spychała, Brendan C. Bender, James Edwin Hall, (unknown), Kwasi A. Ohemeng, (unknown)	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact